Group 1 - Lifecore Biomedical reported a quarterly loss of $0.1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, representing an earnings surprise of -11.11% [1] - The company posted revenues of $36.44 million for the quarter ended May 2025, surpassing the Zacks Consensus Estimate by 1.96%, but down from $37.89 million year-over-year [2] - Lifecore Biomedical has surpassed consensus revenue estimates three times over the last four quarters [2] Group 2 - The stock has added about 4% since the beginning of the year, underperforming the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the coming quarter is -$0.29 on revenues of $25.37 million, and -$0.61 on revenues of $132.88 million for the current fiscal year [7] Group 3 - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 41% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Lifecore Biomedical was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock [6]

Financial Data and Key Metrics Changes - Revenues for Q4 FY2025 were $36.4 million, a decrease of 4% compared to $37.9 million in the prior year period, primarily due to a $5.6 million decrease in CDMO revenues [16][17] - For the full year, revenues were $128.9 million, an increase of 0.5% compared to $128.3 million in the prior year, driven by a $7.1 million increase in manufacturing demand [19][20] - The company recorded a net loss of $1.1 million for Q4 FY2025, compared to a net loss of $7.1 million in the same period last year [18][22] - Adjusted EBITDA for Q4 FY2025 was $9.1 million, a decrease of $1.3 million from $10.4 million in the prior year [18][22] Business Line Data and Key Metrics Changes - CDMO revenues decreased by $5.6 million in Q4 FY2025, primarily due to lower development revenue [16][17] - Hyaluronic acid manufacturing revenues increased by $4.1 million due to increased demand from the largest customer [17] - For the full year, CDMO revenues declined by $6.5 million, primarily due to lower development revenue [19][20] Market Data and Key Metrics Changes - The company is seeing increased demand from its largest customer due to supply chain initiatives, which is expected to contribute to future revenue growth [31][46] - The GLP-1 market is projected to triple by 2030, indicating significant growth potential for the company in this area [32] Company Strategy and Development Direction - The company is focused on three growth strategies: maximizing existing customer business, advancing late-stage development programs, and winning new impactful business [3][4] - A significant inflection point is anticipated in 2027 related to minimum take-or-pay commitments from a current customer, expanding into Asia Pacific markets [4] - The company has signed a new ten-year commercial manufacturing and supply agreement with a late-stage customer, indicating progress in its late-stage pipeline [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's achievements during the transition year and the improvements made in efficiency and productivity [26][15] - The company is positioned to capitalize on the strong demand for pharmaceutical manufacturing in the U.S. and is increasing investments in sales and marketing [46][55] - Management remains confident in achieving a 12% revenue CAGR and increasing EBITDA margins to over 25% in the midterm [2][22] Other Important Information - The company will transition its fiscal year end to align with the calendar year, effective for the 12/31/2025 period [23][24] - Financial guidance for the seven-month transition period from May 26 to December 2025 is expected to be between $74 million to $76 million in revenue and $12 million to $14 million in adjusted EBITDA [24] Q&A Session Summary Question: What is the expected incremental revenue from the largest customer supply chain initiatives? - Management confirmed that the previously mentioned $20 million of incremental revenue is still a relevant figure, with expectations for volumes to ramp up ahead of the minimum volume commitments in 2027 [29][31] Question: Can you provide details on the new GLP-1 agreement? - Management expressed excitement about the collaboration but did not disclose specific terms, noting the GLP-1 market's projected growth [32] Question: What are the expected margins for the next twelve months? - Management indicated that gross margins for the upcoming seven-month period are expected to be in the low 30% range, with improvements anticipated compared to FY2025 [34][35] Question: How are tariff discussions impacting business? - Management views tariff discussions as noise, emphasizing strong U.S. pharmaceutical manufacturing and the company's strategic positioning to capitalize on opportunities [44][46] Question: What is the current number of late-stage projects? - The company currently has 11 late-stage programs, an increase from 10 previously communicated [56] Question: What was the cash flow from operations in Q4? - The company reported positive cash flow from operations of over $5 million and free cash flow of over $3 million for Q4 [58] Question: What is the timeline and cost for the ERP implementation? - The ERP system is targeted to go live in 2026, with an estimated investment of $600,000 to $1 million [60]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 25, 2025, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________. Commission file number: 000-27446 LIFECORE BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other juris ...

[Executive Summary & Corporate Update](index=1&type=section&id=Executive%20Summary%20%26%20Corporate%20Update) [Fiscal Year 2025 Highlights](index=1&type=section&id=Fiscal%20Year%202025%20Highlights) Lifecore Biomedical achieved its fiscal year 2025 revenue guidance of $128.9 million, driven by organizational restructuring, efficiency improvements, and strategic growth initiatives. The company signed nine new programs with new customers, expanding into new modalities beyond ophthalmic therapeutics, and is progressing its late-stage pipeline towards commercialization. Lifecore maintains its mid-term outlook of achieving a 12%+ revenue CAGR and expanding adjusted EBITDA margins to over 25%. - Lifecore Biomedical met its fiscal year 2025 revenue guidance, recording **$128.9 million**[1](index=1&type=chunk) - The company signed **nine new programs** with new customers during fiscal 2025, reflecting growth into modalities beyond traditional ophthalmic therapeutics[1](index=1&type=chunk)[6](index=6&type=chunk) - Lifecore implemented numerous efficiencies, right-sized headcount, and reduced expenses as a percentage of revenue, while increasing revenue per direct labor employee[3](index=3&type=chunk) - Mid-term outlook targets a **12%+ revenue CAGR** and adjusted EBITDA margins exceeding **25%**[3](index=3&type=chunk) [New Business & Operations Update](index=1&type=section&id=New%20Business%20%26%20Operations%20Update) Lifecore continued to make significant operational improvements under new leadership, leading to reduced operational expenses and improved productivity. The company secured nine new programs in FY2025, including three in Q4, and expanded into new therapeutic areas. Post-quarter, new agreements include a late-stage GLP-1 therapeutic product and a Phase 2 dermatology program. A new ERP system is slated for launch in Q1 2026 to further enhance efficiencies and cost savings. - Lifecore signed **three early-stage programs** in Q4 FY2025, including one with a large, multinational pharmaceutical company[6](index=6&type=chunk) - Subsequent to quarter end, Lifecore signed new customer agreements for a late-stage GLP-1 therapeutic product and a Phase 2 dermatology program[6](index=6&type=chunk) - Operational improvements led to reduced expenses and improved productivity, fostering a performance-driven culture[5](index=5&type=chunk) - A new ERP system is planned for launch in Q1 2026, expected to drive further operational efficiencies and cost savings[7](index=7&type=chunk) [Financial and Corporate Announcements](index=2&type=section&id=Financial%20and%20Corporate%20Announcements) Lifecore announced a change in its fiscal year end to align with the calendar year, effective December 31, 2025. This change aims to improve timely reporting alignment with peers, customers, and stakeholders, and coincides with the launch of the new ERP system. - Lifecore will move its fiscal year end to align with the calendar year, effective **December 31, 2025**[8](index=8&type=chunk) - The fiscal year change is intended to improve timely reporting alignment with peer companies, customers, and stakeholders, and aligns with the new ERP system launch[8](index=8&type=chunk) [Consolidated Financial Results](index=2&type=section&id=Consolidated%20Financial%20Results) [Fourth Quarter Fiscal 2025 Financial Results](index=2&type=section&id=Fourth%20Quarter%20Fiscal%202025%20Financial%20Results) In Q4 FY2025, Lifecore reported a 4% decrease in total revenues to $36.4 million, primarily due to a decline in CDMO revenues, partially offset by increased HA manufacturing demand. Gross profit decreased by $3.3 million, while SG&A expenses saw a $3.2 million reduction. The company recorded a net loss of $1.1 million, a significant improvement from the prior year's $7.1 million loss, and Adjusted EBITDA decreased by $1.3 million. Q4 Fiscal 2025 Key Financials (YoY Comparison) | Metric | Q4 FY2025 (in thousands) | Q4 FY2024 (in thousands) | Change (YoY) | | :-------------------------------- | :----------------------- | :----------------------- | :----------- | | Total Revenues | $36,444 | $37,886 | -4% | | CDMO Revenues | - | -$5,600 (decrease) | - | | HA Manufacturing Revenues | - | +$4,100 (increase) | - | | Gross Profit | $13,982 | $17,272 | -$3,290 | | Selling, General & Administrative Expenses | $8,980 | $12,226 | -$3,246 | | Interest Expense, net | $5,500 | $5,800 | -$300 | | Net Loss | $(1,147) | $(7,085) | +$5,938 | | Loss per Diluted Share | $(0.06) | $(0.19) | +$0.13 | | Adjusted EBITDA | $9,052 | $10,410 | -$1,358 | - The decrease in CDMO revenues was primarily due to the completion of a discrete development project and timing of customer project lifecycles[9](index=9&type=chunk) - HA manufacturing revenues increased due to increased demand from Lifecore's largest customer's supply chain initiatives[9](index=9&type=chunk) - Net loss improved significantly due to a gain from the settlement of a legacy business obligation and a favorable debt derivative adjustment[13](index=13&type=chunk) [Full Year Fiscal 2025 Financial Results](index=3&type=section&id=Full%20Year%20Fiscal%202025%20Financial%20Results) For the full fiscal year 2025, Lifecore's revenues increased slightly by 0.5% to $128.9 million, driven by HA manufacturing demand, offsetting a decline in CDMO revenues. Gross profit decreased by $1.6 million. SG&A expenses rose by $3.5 million, mainly due to increased non-cash stock-based compensation. The company reported a net loss of $38.7 million, a significant shift from the prior year's net income, largely influenced by a loss on asset disposal and the absence of a large favorable debt derivative adjustment seen in the prior year. Adjusted EBITDA also saw a slight decrease. Full Year Fiscal 2025 Key Financials (YoY Comparison) | Metric | FY2025 (in thousands) | FY2024 (in thousands) | Change (YoY) | | :-------------------------------- | :-------------------- | :-------------------- | :----------- | | Total Revenues | $128,867 | $128,261 | +0.5% | | HA Manufacturing Revenues | - | +$7,100 (increase) | - | | CDMO Revenues | - | -$6,500 (decrease) | - | | Gross Profit | $40,298 | $41,850 | -$1,552 | | Selling, General & Administrative Expenses | $44,046 | $40,463 | +$3,583 | | Interest Expense, net | $21,835 | $18,090 | +$3,745 | | Net Loss (Income) | $(38,717) | $12,013 | -$50,730 | | Loss (Income) per Diluted Share | $(1.27) | $0.33 | -$1.60 | | Adjusted EBITDA | $19,481 | $20,206 | -$725 | - The increase in SG&A expenses was primarily due to a **$3.7 million increase** in non-cash stock-based compensation related to new hire performance stock unit grants[16](index=16&type=chunk) - The significant shift from net income to net loss was influenced by a **$7.7 million loss on asset disposal** in FY2025 and the absence of a **$39.5 million favorable non-cash fair market value adjustment** to debt derivative liability present in FY2024[18](index=18&type=chunk) [Financial Guidance](index=3&type=section&id=Financial%20Guidance) [Calendar Year 2025 Transition Period Financial Guidance](index=3&type=section&id=Calendar%20Year%202025%20Transition%20Period%20Financial%20Guidance) For the seven-month transition period from May 26 to December 31, 2025, Lifecore projects revenues between $74 million and $76 million. The company expects a net loss ranging from $19.8 million to $17.8 million and Adjusted EBITDA between $12 million and $14 million. Calendar Year 2025 Transition Period Guidance (May 26 - Dec 31, 2025) | Metric | Estimated Range (in millions) | | :---------------- | :---------------------------- | | Revenue | $74 - $76 | | Net Loss | $(19.8) - $(17.8) | | Adjusted EBITDA | $12 - $14 | - This guidance considers existing market forces, contracts, timing of customer orders, and the company's current beliefs regarding new business development revenue growth and diversification[20](index=20&type=chunk) [Company Information](index=4&type=section&id=Company%20Information) [Earnings Webcast](index=4&type=section&id=Earnings%20Webcast) Lifecore Biomedical hosted a conference call on August 7, 2025, to discuss its Q4 and FY2025 financial results. A webcast of the event is available on the company's investor relations website. - A conference call was held on **August 7, 2025**, to discuss Q4 and FY2025 financial results[22](index=22&type=chunk) - The webcast is accessible via Lifecore's Investor Events & Presentations page and will be archived for **30 days**[22](index=22&type=chunk) [About Lifecore Biomedical](index=4&type=section&id=About%20Lifecore%20Biomedical) Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products, including complex formulations, in syringes, vials, and cartridges. With over 40 years of expertise in premium, injectable-grade hyaluronic acid, Lifecore partners with global biopharmaceutical and biotechnology companies. - Lifecore Biomedical is a fully integrated CDMO offering highly differentiated capabilities in sterile injectable pharmaceutical products[23](index=23&type=chunk) - The company is a leading manufacturer of premium, injectable-grade hyaluronic acid, with over **40 years of expertise**[23](index=23&type=chunk) [Non-GAAP Financial Information](index=4&type=section&id=Non-GAAP%20Financial%20Information) [Definition and Use of Non-GAAP Measures](index=4&type=section&id=Definition%20and%20Use%20of%20Non-GAAP%20Measures) Lifecore Biomedical uses Adjusted EBITDA as a non-GAAP financial measure to supplement its GAAP financial statements. This measure excludes certain items not reflective of core or ongoing operations, providing additional insights into operational trends and facilitating period-over-period comparisons. Management utilizes Adjusted EBITDA for monitoring operations, decision-making, planning, forecasting, and compensation, but cautions that it should not be considered in isolation or as a substitute for GAAP measures. - Adjusted EBITDA is a non-GAAP measure that excludes certain items from Net income (loss) to provide insights into core operations[24](index=24&type=chunk)[27](index=27&type=chunk) - Management uses Adjusted EBITDA for monitoring trends, comparing operating results, financial and operational decision-making, planning, forecasting, and compensation decisions[27](index=27&type=chunk) - Non-GAAP measures should not be considered in isolation or as a substitute for comparable GAAP measures and may differ from similar measures used by other companies[28](index=28&type=chunk) [Important Cautions Regarding Forward-Looking Statements](index=4&type=section&id=Important%20Cautions%20Regarding%20Forward-Looking%20Statements) This press release contains forward-looking statements subject to various risks and uncertainties that could cause actual results to differ materially from expectations. These risks include timing of expenses and revenue, ability to maintain customer relationships, grow new business, comply with credit covenants, raise capital, macroeconomic impacts, supplier performance, personnel retention, regulatory compliance, and litigation outcomes. Readers are advised to refer to the company's SEC filings, including the 2025 Form 10-K, for additional risk factors. - Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially[29](index=29&type=chunk)[30](index=30&type=chunk) - Key risk factors include timing of expenses and revenue, customer relationships, new business growth, compliance with credit agreements, capital raising, macroeconomic events, supplier performance, personnel retention, regulatory compliance, and litigation[30](index=30&type=chunk) - The company does not undertake any obligation to update forward-looking statements, except as required by law[30](index=30&type=chunk) [Consolidated Financial Statements](index=6&type=section&id=Consolidated%20Financial%20Statements) [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) As of May 25, 2025, Lifecore's total assets decreased to $239.3 million from $254.0 million in the prior year. This was primarily driven by a decrease in property, plant, and equipment and inventory, partially offset by an increase in current portion of note receivable and contract assets. Total liabilities also decreased to $191.9 million from $200.1 million, mainly due to reductions in accounts payable and debt, net of current portion. Total stockholders' equity significantly decreased to $1.3 million from $11.3 million. Consolidated Balance Sheet Highlights (in thousands) | Metric | May 25, 2025 | May 26, 2024 | Change | | :------------------------------------------ | :----------- | :----------- | :------- | | Total Assets | $239,342 | $253,960 | -$14,618 | | Current Assets | $85,677 | $81,033 | +$4,644 | | Property, Plant, and Equipment, net | $129,006 | $149,165 | -$20,159 | | Total Liabilities | $191,909 | $200,058 | -$8,149 | | Current Liabilities | $30,178 | $38,872 | -$8,694 | | Debt, net of current portion, related party | $121,198 | $100,819 | +$20,379 | | Total Stockholders' Equity | $1,336 | $11,315 | -$9,979 | [Consolidated Statements of Operations](index=7&type=section&id=Consolidated%20Statements%20of%20Operations) The Consolidated Statements of Operations show a net loss of $1.1 million for Q4 FY2025 and $38.7 million for the full FY2025. Total revenues for the full year were $128.9 million, a slight increase from the prior year. Gross profit decreased for both the quarter and the full year. Operating income for Q4 was $5.3 million, while the full year saw an operating loss of $17.2 million. The full year net loss was significantly impacted by increased interest expense and a loss on asset disposal, contrasting with a net income in the prior year that benefited from a large fair value adjustment. Consolidated Statements of Operations Highlights (in thousands) | Metric | Three months ended May 25, 2025 | Three months ended May 26, 2024 | Year ended May 25, 2025 | Year ended May 26, 2024 | | :------------------------------------------ | :------------------------------ | :------------------------------ | :---------------------- | :---------------------- | | Total Revenues | $36,444 | $37,886 | $128,867 | $128,261 | | Gross Profit | $13,982 | $17,272 | $40,298 | $41,850 | | Operating income (loss) | $5,327 | $2,147 | $(17,245) | $(8,844) | | Net (loss) income | $(1,147) | $(7,085) | $(38,717) | $12,013 | | Diluted (loss) income per share | $(0.06) | $(0.19) | $(1.27) | $0.33 | - Full year interest expense, net, increased to **$21.8 million** in FY2025 from **$18.1 million** in FY2024, primarily due to Alcon term loans[17](index=17&type=chunk)[35](index=35&type=chunk) - The year ended May 25, 2025, included a **$6.9 million loss on sale or disposal of assets**, which was not present in the prior year[35](index=35&type=chunk) [Non-GAAP Financial Reconciliations](index=9&type=section&id=Non-GAAP%20Financial%20Reconciliations) [Adjusted EBITDA Reconciliation](index=9&type=section&id=Adjusted%20EBITDA%20Reconciliation) Lifecore provides a reconciliation of Net (loss) income to Adjusted EBITDA, defining Adjusted EBITDA by excluding items such as interest expense, income tax, depreciation, stock-based compensation, changes in fair value of debt derivatives, financing fees, loss on asset disposal, reorganization and restructuring costs, and other specific non-recurring or non-operational items. For Q4 FY2025, Adjusted EBITDA was $9.1 million, and for the full FY2025, it was $19.5 million. - Adjusted EBITDA is defined as net income or loss before interest expense, income tax, depreciation and amortization, stock-based compensation, change in fair value of debt derivatives, financing fees, loss on sale or disposal of assets, reorganization costs, restructuring costs, franchise tax, contract cancellation costs, income from discontinued operations, stockholder activist settlement costs, and start-up costs[39](index=39&type=chunk) Adjusted EBITDA Reconciliation (in thousands) | Metric | Three months ended May 25, 2025 | Three months ended May 26, 2024 | Year ended May 25, 2025 | Year ended May 26, 2024 | | :------------------------------------------ | :------------------------------ | :------------------------------ | :---------------------- | :---------------------- | | Net (loss) income (GAAP) | $(1,147) | $(7,085) | $(38,717) | $12,013 | | Interest expense, net | $5,521 | $5,790 | $21,835 | $18,090 | | Income tax expense (benefit) | $33 | $(57) | $43 | $183 | | Depreciation and amortization | $1,913 | $2,014 | $8,027 | $7,954 | | Stock-based compensation | $1,815 | $1,597 | $10,158 | $6,201 | | Change in fair value of debt derivatives | $1,091 | $2,400 | $(409) | $(39,500) | | Loss on sale or disposal of assets | $91 | — | $7,729 | — | | Adjusted EBITDA | $9,052 | $10,410 | $19,481 | $20,206 | [Remainder of 2025 Guidance Due to Fiscal Year Change and Reconciliation](index=10&type=section&id=Remainder%20of%202025%20Guidance%20Due%20to%20Fiscal%20Year%20Change%20and%20Reconciliation) Lifecore provides a reconciliation for its financial guidance for the seven-month transition period (May 26 to December 31, 2025), aligning with the fiscal year change. The reconciliation details the adjustments from estimated Net loss to estimated Adjusted EBITDA, using similar exclusions as its historical definition. The estimated Net loss range is $(19.8) million to $(17.8) million, reconciling to an Adjusted EBITDA range of $12 million to $14 million. - The fiscal year end is moving to **December 31, 2025**, to align with the calendar year, peer companies, customers, and the launch of a new ERP system[41](index=41&type=chunk) Estimated Adjusted EBITDA Reconciliation for 7-month Transition Period (in thousands) | Metric | May 26, 2025 to December 31, 2025 (estimate) | | :------------------------------------------ | :------------------------------------------- | | Net (loss) (GAAP) | $(19,800) – $(17,800) | | Interest expense, net | $15,800 | | Depreciation and amortization | $5,200 | | Stock-based compensation | $5,300 | | Change in fair value of debt derivatives | $2,100 | | Reorganization costs | $3,300 | | Franchise tax equivalent to income tax | $100 | | Adjusted EBITDA | $12,000 – $14,000 |

Company Overview - Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [3] Upcoming Financial Results - Lifecore will report its financial results for the fourth quarter and fiscal year 2025 on August 7, 2025, after market close [1] - A webcast hosted by Lifecore's senior management team will take place at 4:30 p.m. Eastern Time on the same day to discuss the results [1][2] Webcast Access - Investors can listen to the live webcast or access the archived version on Lifecore's Investor Events & Presentations page [2] - The archived version will be available for 30 days following the live event [2] Contact Information - Lifecore's investor relations contact is Stephanie Diaz from Vida Strategic Partners, reachable at 415-675-7401 [4] - Media inquiries can be directed to Tim Brons at 415-675-7402 [4] - Ryan D. Lake serves as the CFO of Lifecore Biomedical and can be contacted at 952-368-6244 [4]

Core Insights - Lifecore Biomedical, Inc. has signed a new 10-year commercial manufacturing and supply agreement with an existing customer to support the advancement of a novel ophthalmic therapeutic towards commercialization [1][2] - The agreement is part of Lifecore's growth strategy, emphasizing the importance of late-stage customer projects that are nearing potential commercialization [2] - A multi-million-dollar statement of work has also been signed, detailing various fill and finish CDMO services to advance the drug candidate towards regulatory approval [2] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and partners with global and emerging biopharmaceutical and biotechnology companies [3]

April 2025 Important Information Regarding Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements, among other things, relate to the Company's growth drivers and expected levels of our organic growth; the impact of our investment in development and commercial initiatives; financial guidance, including timing of revenues and EBITDA; our ability to ...

Core Insights - Lifecore Biomedical has received the remaining $10 million from the sale of its excess high-speed, multi-purpose 10-head isolator filler, completing a $17 million transaction ahead of schedule [1][2] - The company emphasizes its disciplined capital management approach and the positive momentum from recent operational enhancements, including the installation of a high-speed 5-head filler with a capacity of up to $300 million in annual revenue [2] Financial Developments - The total proceeds from the sale of the 10-head isolator filler amounted to $17 million, with $7 million received at the close of the transaction in early 2025 [1][2] - The accelerated payment from the buyer was made as a lump sum rather than the originally planned 18-month installment plan [1] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies [3]

Core Insights - Lifecore Biomedical has appointed Mark DaFonseca as chief commercial officer, bringing nearly 30 years of pharmaceutical industry experience, particularly in contract development and manufacturing organizations (CDMOs) [1][2] - DaFonseca will focus on executing a three-pronged growth strategy aimed at enhancing Lifecore's brand, expanding customer partnerships, and growing the business portfolio through new collaborations [1][3] Company Background - Lifecore Biomedical is a fully integrated CDMO specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [7] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global biopharmaceutical and biotechnology companies [7] Leadership Experience - Prior to joining Lifecore, DaFonseca held significant roles at CordenPharma, AmbioPharma, and CoreRx, where he led sales, marketing, and project management efforts [2] - His track record includes consistently exceeding key performance indicators in various sales leadership positions within the CDMO sector [2] Strategic Goals - DaFonseca expressed eagerness to leverage Lifecore's assets to strategically grow the business by expanding current customer relationships and increasing the overall customer base [4] - The company aims to enhance its market presence and address the industry's capacity needs through investments in state-of-the-art facilities and equipment [4] Compensation Details - As part of his appointment, Lifecore will grant DaFonseca a restricted stock unit (RSU) award for 20,000 shares and an option for 30,000 shares of common stock [4][5] - The RSU will vest on the third anniversary of the grant date, while the stock option will have a vesting schedule based on continued employment [6]

Core Insights - Lifecore Biomedical, Inc. will participate in the CDMO Live 2025 conference, a key event for the biopharma outsourcing industry, scheduled for May 7-8, 2025, in Rotterdam, Netherlands [1] - Jackie Klecker, Lifecore's executive vice president, will lead a discussion on transforming quality management into a strategic driver for CDMO partnerships, leveraging her 30 years of industry experience [2] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies across various therapeutic categories [3]